# An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis

> **NCT03896295** · PHASE2 · TERMINATED · sponsor: **Momenta Pharmaceuticals, Inc.** · enrollment: 37 (actual)

## Conditions studied

- Generalized Myasthenia Gravis

## Interventions

- **DRUG:** M281

## Key facts

- **NCT ID:** NCT03896295
- **Lead sponsor:** Momenta Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-06
- **Primary completion:** 2020-12-09
- **Final completion:** 2020-12-09
- **Target enrollment:** 37 (ACTUAL)
- **Why stopped:** Study was originally halted due to the COVID-19 pandemic. The study was later terminated prematurely as the participants will have the option to enter into an open-label extension portion of a planned future study. It was not due to safety concerns.
- **Last updated:** 2023-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03896295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03896295, "An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03896295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*